Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...

Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

ALAMEDA, Calif., February 25, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge fund ...

Like its predecessor, this one is capped at $500 million. After market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million ...

After market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million worth of its common stock before this coming Dec. 31.

Cutting corners: Researchers at Imperial College London say an artificial intelligence-based science tool created by Google needed just 48 hours to solve a problem that took them roughly a decade ...